Last update :
19/11/2024
Anticancer drug   Cetuximab  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Erbitux Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Hungary, Iceland, India, Iran, Ireland, Italy, Japan, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Republic of South Africa, Romania, Spain, Sweden, Switzerland, Turkey, United States of America, Venezuela
References   injection   References : Cetuximab  
Type Publication
2220 Manufacturer Cétuximab (Erbitux®) - Dossier scientifique
Merck Serono 2015
2296 Manufacturer Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
4755 Journal Vieillard V, Le Guyader G, Jallades A, Astier A.
Extended physicochemical stability of cetuximab in opened vials and infusion bags when stored at 4°C and 25°C.
J Oncol Pharm Practice 2023
4819 Journal Carpanese D, Rossi V, Di Paolo V, Quintieri L, Penna Zuccolotto G, Sebellin J, Saran C, Pipitone F, Miolo G, de Diana E et al.
Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations.
Int J Pharm 2024 ; 649: 123643.

  Mentions Légales